Steven Seedhouse
Stock Analyst at Raymond James
(3.91)
# 825
Out of 5,182 analysts
170
Total ratings
49.43%
Success rate
10.25%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $23 | $12.80 | +79.69% | 4 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Upgrades: Strong Buy | $63 → $123 | $83.67 | +47.01% | 5 | Mar 10, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $8.86 | +193.45% | 2 | Oct 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $94.06 | -12.82% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.52 | +32.98% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $28.22 | -0.78% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.67 | +498.80% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $32.39 | +221.09% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $5.72 | +284.62% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.48 | +845.95% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $129.26 | -28.05% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $37.11 | +83.24% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $40.99 | +158.60% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.97 | +151.26% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $18.16 | +208.37% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.20 | +331.82% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $5.30 | +315.09% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.06 | +455.56% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.43 | +920.41% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $83.85 | -54.68% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.34 | +1,349.70% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $66.11 | -42.52% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $8.87 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.24 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.59 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $23.96 | +1,026.88% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $183.38 | - | 2 | Apr 23, 2020 |
Korro Bio
Mar 13, 2026
Upgrades: Outperform
Price Target: $23
Current: $12.80
Upside: +79.69%
Dianthus Therapeutics
Mar 10, 2026
Upgrades: Strong Buy
Price Target: $63 → $123
Current: $83.67
Upside: +47.01%
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $8.86
Upside: +193.45%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $94.06
Upside: -12.82%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.52
Upside: +32.98%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $28.22
Upside: -0.78%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.67
Upside: +498.80%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $32.39
Upside: +221.09%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $5.72
Upside: +284.62%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.48
Upside: +845.95%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $129.26
Upside: -28.05%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $37.11
Upside: +83.24%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $40.99
Upside: +158.60%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.97
Upside: +151.26%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $18.16
Upside: +208.37%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.20
Upside: +331.82%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $5.30
Upside: +315.09%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.06
Upside: +455.56%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.43
Upside: +920.41%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $83.85
Upside: -54.68%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.34
Upside: +1,349.70%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $66.11
Upside: -42.52%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $8.87
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.24
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $23.96
Upside: +1,026.88%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $183.38
Upside: -